Not applicableUnknownNCT05716672What this trial is testingImpact of Lazertinib Dose Modification on Effectiveness and SafetyWho this might be right forNon-small Cell Lung Cancer Pusan National University Hospital 200
Testing effectiveness (Phase 2)Active Not RecruitingNCT05078931What this trial is testingEvaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC PatientsWho this might be right forNSCLC Shanghai Chest Hospital 35
Not applicableStudy completedNCT04807595What this trial is testingEstimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low StatusWho this might be right forBreast Cancer AstraZeneca 798
Post-approval studies (Phase 4)Study completedNCT03853551What this trial is testingOsimertinib Study in Indian PatientsWho this might be right forNon Small Cell Lung Cancer (NSCLC) AstraZeneca 60
Testing effectiveness (Phase 2)Study completedNCT03433027What this trial is testingBB-401 in Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaWho this might be right forHead and Neck Squamous Cell Carcinoma Benitec Biopharma, Inc. 16
Large-scale testing (Phase 3)Active Not RecruitingNCT06305754What this trial is testingSacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)Who this might be right forNon-small Cell Lung Cancer (NSCLC) Merck Sharp & Dohme LLC 550
Testing effectiveness (Phase 2)Active Not RecruitingNCT05712902What this trial is testingSunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)Who this might be right forNon-Small Cell Lung Cancer Dizal Pharmaceuticals 104
Large-scale testing (Phase 3)Looking for participantsNCT07738172What this trial is testingOsimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung CancerWho this might be right forLung Neoplasms, Non-Small Cell Lung Cancer National Taiwan University Hospital 154
Testing effectiveness (Phase 2)Ended earlyNCT03499353What this trial is testingTalazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast CancerWho this might be right forEarly Breast Cancer Pfizer 61
Testing effectiveness (Phase 2)Looking for participantsNCT07659795What this trial is testingVS-7375 in Patients With KRAS G12D-Mutated Colorectal CancerWho this might be right forColorectal Cancer Verastem, Inc. 150
Large-scale testing (Phase 3)Active Not RecruitingNCT05870319What this trial is testingA Phase III Study of SKB264 for EGFR Mutant NSCLC PatientsWho this might be right forNon-small Cell Lung Cancer Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 376
Large-scale testing (Phase 3)UnknownNCT01407822What this trial is testingErlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung CancerWho this might be right forNon-small Cell Lung Cancer Guangdong Association of Clinical Trials 72
Testing effectiveness (Phase 2)UnknownNCT01312337What this trial is testingIressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC)Who this might be right forNonsmall Cell Lung Cancer Samsung Medical Center 92
Large-scale testing (Phase 3)Study completedNCT00063141What this trial is testingStudy of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal CancerWho this might be right forColorectal Cancer Eli Lilly and Company 1,302
Large-scale testing (Phase 3)Active Not RecruitingNCT04557462What this trial is testingA Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA NephropathyWho this might be right forPrimary IgA Nephropathy Novartis Pharmaceuticals 448
Not applicableStudy completedNCT07086196What this trial is testingReal-World Outcomes of Ribociclib in First-Line Treatment for Metastatic HR+/HER2- Breast CancerWho this might be right forMetastatic HR+/HER2- Breast Cancer Novartis Pharmaceuticals 350
Not applicableStudy completedNCT02994888What this trial is testingPROSPECT-C: A Study of Biomarkers of Response or Resistance to Anti-EGFR Therapies in Metastatic Colorectal CancerWho this might be right forMetastatic Colorectal Cancer Royal Marsden NHS Foundation Trust 47
Testing effectiveness (Phase 2)Looking for participantsNCT06945705What this trial is testingA Clinical Trial of Furmonertinib Combined With Anlotinib as First-line Treatment for Advanced NSCLC With EGFR-sensitive Mutations and Brain MetastasisWho this might be right forNSCLC Henan Cancer Hospital 146
Early research (Phase 1)Study completedNCT04568902What this trial is testingStudy of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast CancerWho this might be right forBreast Neoplasms Eisai Co., Ltd. 33
Testing effectiveness (Phase 2)Study completedNCT03448731What this trial is testingSkin Toxicity in Patients With Metastatic Colorectal Cancer Treated With Anti-EGFR and Chemotherapy (DERMIA)Who this might be right forSkin Toxicity Fundacion CRIS de Investigación para Vencer el Cáncer 34